Merck tumbles on drug study update
January 13, 2011 at 13:05 PM EST
Shares of Merck are falling on news that monitors have recommended the company shut down a key clinical trial of its new blood-thinner vorapaxar and discontinue use in stroke patients enrolled in a second study.
